Article Text

Download PDFPDF
P177 What are the real-world outcomes of locally advanced vulval cancer patients who receive neoadjuvant chemotherapy to downstage their disease?
  1. K Baillie1,
  2. C Crearie1,
  3. J Laskey1,
  4. M Bennie2,3,
  5. A Sadozye1,
  6. R Harrand1,
  7. K Burton4,
  8. N Siddiqui4,
  9. N Reed1 and
  10. K Graham1
  1. 1Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde
  2. 2Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow
  3. 3Public Health and Intelligence Strategic Business Unit, NHS National Services Scotland, Edinburgh
  4. 4Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, UK


Introduction/Background Limited studies suggest that locally advanced vulval cancer may be rendered more operable with neoadjuvant chemotherapy (NACT). In the West of Scotland Cancer Network (WoSCAN), NACT is offered to women with sphincter threatening disease. A previous local audit in 2012 reported an operability rate of 35% and median overall survival (OS) of 20 months, following NACT. This study aimed to identify the proportion of patients who proceed to tailored surgery with wide local excision ± groin node dissection following NACT for vulval cancer in the real-world setting.

Methodology Data were collected retrospectively from electronic clinical records of WoSCAN patients who commenced NACT between January 2012 and December 2016. Statistical analysis was performed using R®. OS was estimated using Kaplan-Meier method and Cox’s proportional-hazards models used to calculate unadjusted hazard ratios (HR).

Results 57 patients were identified with a median age of 65 years (range 35–88). Cisplatin/Capecitabine was the most common NACT regimen (80.7%); a median of 3 cycles were administered. 43.9% proceeded to surgery, 35.1% received primary (chemo)radiotherapy and 21.2% did not receive any definitive therapy. Exenteration was avoided in all cases. Data were censored in February 2018 at which time 29 patients (50.9%) remained alive and 35.1% required further treatment for relapse. Median OS was 39.3 months. Survival was shorter in patients receiving NACT alone (HR 3.44 (95% CI 1.33–8.87)) but not significantly different between surgery and radiotherapy groups.

Conclusion Over 40% of women received surgical resection with sphincter preservation. Our operability rate has increased and OS is longer than our previous audit, reasons for which are currently being explored. Survival with NACT followed by radical (chemo)radiotherapy was comparable to surgery. Local relapse remains an issue and close follow up is advised as salvage therapy may be indicated.

Disclosure This study was funded by the Scottish Government. The authors declare no competing interests.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.